Home
Scholarly Works
Phase I clinical study of orally-dosed HBW-3220 in...
Conference

Phase I clinical study of orally-dosed HBW-3220 in patients with relapsed/refractory B-cell lymphoma

Authors

Li Y; Mao Y; Liu G; Li J; Liu Q; Lee N

Volume

41

Publisher

LIPPINCOTT WILLIAMS & WILKINS

Publication Date

June 1, 2023

Name of conference

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

Conference place

IL, Chicago

Conference start date

June 2, 2023

Conference end date

June 6, 2023

Conference proceedings

JOURNAL OF CLINICAL ONCOLOGY

Issue

16

ISSN

0732-183X

Labels

Fields of Research (FoR)

Contact the Experts team